Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Jazz Pharmaceuticals (JAZZ)

Jazz swings to $718.5 million Q2 net loss on $905.4 million Chimerix charge

Mixed Impact 4 of 5 earnings Written later

Jazz reported second-quarter 2025 total revenues of $1.05 billion, up 2% from a year earlier, but posted a GAAP net loss of $718.5 million after a $905.4 million acquired in-process R&D charge tied to the Chimerix acquisition. The company lowered the top end of its full-year 2025 revenue guidance to $4.15 billion to $4.30 billion and named Renee Gala President and CEO effective August 11, 2025.

Key points

  • Q2 2025 total revenues were $1.05 billion, up from $1.02 billion in Q2 2024.
  • GAAP net loss was $718.5 million, or $11.74 per diluted share, versus GAAP net income of $168.6 million, or $2.49 per share, in Q2 2024.
  • The net loss includes a $905.4 million acquired IPR&D charge for dordaviprone, which reduced results by $14.78 per share on a GAAP basis.
  • 2025 total revenue guidance is now $4.15 billion to $4.30 billion, down from $4.15 billion to $4.40 billion at the top end; GAAP net loss guidance is $(565) million to $(450) million.

The filing

CompanyJazz Pharmaceuticals (JAZZ)
Form8-K, current report
Filed with the SECAug 5, 2025, 4:08 PM ET
Accession number0001232524-25-000061

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:11 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 05, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.